Autolus Therapeutics PLC
AUTL1.420USD
+0.100+7.58%
Cierre 02/06, 16:00（ET）Cotizaciones retrasadas 15 min
377.92MCap. mercado
PérdidaP/E TTM
Más Datos de Autolus Therapeutics PLC Compañía
Autolus Therapeutics plc is a United Kingdom-based early commercial-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. The Company has an approved commercial product, AUCATZYL, for the treatment of adult patients with r/r B-ALL. Using a suite of proprietary and modular T cell programming technologies, it is also developing five programs in seven hematological and solid tumor indications and one autoimmune indication. It is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and attack and eliminate these cells. Its product pipeline includes obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting TRBC 1 and TRBC 2.
Información de Autolus Therapeutics PLC
Símbolo de cotizaciónAUTL
Nombre de la empresaAutolus Therapeutics PLC
Fecha de salida a bolsaJun 22, 2018
Director ejecutivoItin (Christian Martin)
Número de empleados647
Tipo de seguridadDepository Receipt
Fin del año fiscalJun 22
DirecciónThe Mediaworks
CiudadLONDON
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited Kingdom
Código postalW12 7FP
Teléfono442038296230
Sitio Webhttps://www.autolus.com/
Símbolo de cotizaciónAUTL
Fecha de salida a bolsaJun 22, 2018
Director ejecutivoItin (Christian Martin)
Ejecutivos de Autolus Therapeutics PLC
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Cynthia M. Butitta
Ms. Cynthia M. Butitta
Non-Executive Independent Director
Non-Executive Independent Director
10.00K
--
Mr. Brent Rice
Mr. Brent Rice
Senior Vice President, Chief Commercial Officer
Senior Vice President, Chief Commercial Officer
9.40K
--
Dr. Christian Martin Itin, Ph.D.
Dr. Christian Martin Itin, Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Mr. Martin Pule
Mr. Martin Pule
Founder, Senior Vice President, Chief Scientific Officer
Founder, Senior Vice President, Chief Scientific Officer
--
--
Mr. Christopher Vann
Mr. Christopher Vann
Chief Operating Officer, Senior Vice President
Chief Operating Officer, Senior Vice President
--
--
Mr. David Brochu
Mr. David Brochu
Senior Vice President, Chief Technical Officer
Senior Vice President, Chief Technical Officer
--
--
Mr. John Edward Berriman
Mr. John Edward Berriman
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Linda C. Bain
Ms. Linda C. Bain
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. William D. (Bill) Young, Ph.D.
Mr. William D. (Bill) Young, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Elisabeth (Lis) Leiderman, M.D.
Dr. Elisabeth (Lis) Leiderman, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Cynthia M. Butitta
Ms. Cynthia M. Butitta
Non-Executive Independent Director
Non-Executive Independent Director
10.00K
--
Mr. Brent Rice
Mr. Brent Rice
Senior Vice President, Chief Commercial Officer
Senior Vice President, Chief Commercial Officer
9.40K
--
Dr. Christian Martin Itin, Ph.D.
Dr. Christian Martin Itin, Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Mr. Martin Pule
Mr. Martin Pule
Founder, Senior Vice President, Chief Scientific Officer
Founder, Senior Vice President, Chief Scientific Officer
--
--
Mr. Christopher Vann
Mr. Christopher Vann
Chief Operating Officer, Senior Vice President
Chief Operating Officer, Senior Vice President
--
--
Mr. David Brochu
Mr. David Brochu
Senior Vice President, Chief Technical Officer
Senior Vice President, Chief Technical Officer
--
--
Desglose de ingresos
Divisa: USDActualizado: mar., 6 de ene
Divisa: USDActualizado: mar., 6 de ene
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
La empresa aún no ha revelado los datos relevantes.
Por regiónUSD
Nombre
Ganancia
Proporción
United States
21.14M
99.76%
Europe
50.00K
0.24%
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.
Estadísticas de accionistas
Actualizado: mar., 2 de dic
Actualizado: mar., 2 de dic
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Syncona Investment Management Limited
11.55%
MAK Capital One, LLC
10.10%
Clarus Ventures, LLC
7.70%
Syncona Portfolio Ltd
6.25%
Armistice Capital LLC
5.86%
Otro
58.54%
Accionistas
Accionistas
Proporción
Syncona Investment Management Limited
11.55%
MAK Capital One, LLC
10.10%
Clarus Ventures, LLC
7.70%
Syncona Portfolio Ltd
6.25%
Armistice Capital LLC
5.86%
Otro
58.54%
Tipos de accionistas
Accionistas
Proporción
Hedge Fund
23.61%
Investment Advisor
23.56%
Investment Advisor/Hedge Fund
8.97%
Venture Capital
8.06%
Sovereign Wealth Fund
5.64%
Holding Company
5.55%
Research Firm
1.83%
Private Equity
1.74%
Pension Fund
0.07%
Otro
20.97%
Participación institucional
Actualizado: lun., 8 de dic
Actualizado: lun., 8 de dic
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
230
194.47M
90.55%
+128.60K
2025Q3
237
202.34M
94.14%
-20.86M
2025Q2
235
223.88M
91.00%
-2.80M
2025Q1
228
230.12M
90.84%
-11.63M
2024Q4
235
229.60M
92.37%
-10.27M
2024Q3
225
234.01M
89.22%
+30.38M
2024Q2
227
202.70M
79.95%
+2.45M
2024Q1
217
200.05M
58.18%
+45.35M
2023Q4
191
140.21M
76.10%
+4.14M
2023Q3
169
139.76M
70.07%
+377.17K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Syncona Investment Management Limited
30.73M
11.55%
+30.73M
--
Sep 30, 2024
MAK Capital One, LLC
26.89M
10.1%
+869.89K
+3.34%
Dec 01, 2025
Clarus Ventures, LLC
20.49M
7.7%
--
--
Sep 30, 2025
Syncona Portfolio Ltd
16.64M
6.25%
--
--
Sep 30, 2025
Armistice Capital LLC
15.60M
5.86%
+3.60M
+30.00%
Sep 30, 2025
Qatar Investment Authority
15.00M
5.64%
--
--
Mar 01, 2025
PPF Group N.V.
14.78M
5.55%
+170.00K
+1.16%
Oct 24, 2024
Polygon Management Ltd.
9.50M
3.57%
--
--
Sep 30, 2025
Schroder Investment Management Ltd. (SIM)
8.43M
3.17%
+4.82M
+133.71%
Sep 30, 2025
Citadel Advisors LLC
6.04M
2.27%
+5.04M
+501.79%
Sep 30, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
Invesco NASDAQ Future Gen 200 ETF
0.56%
Virtus LifeSci Biotech Clinical Trials ETF
0.49%
ALPS Medical Breakthroughs ETF
0.17%
iShares Health Innovation Active ETF
0.07%
ProShares Ultra Nasdaq Biotechnology
0.03%
Invesco Nasdaq Biotechnology ETF
0.03%
iShares Biotechnology ETF
0.02%
SPDR S&P International Small Cap ETF
0.01%
Tema Oncology ETF
0%
Fidelity Fundamental Small-Mid Cap ETF
0%
Ver más
Invesco NASDAQ Future Gen 200 ETF
Proporción0.56%
Virtus LifeSci Biotech Clinical Trials ETF
Proporción0.49%
ALPS Medical Breakthroughs ETF
Proporción0.17%
iShares Health Innovation Active ETF
Proporción0.07%
ProShares Ultra Nasdaq Biotechnology
Proporción0.03%
Invesco Nasdaq Biotechnology ETF
Proporción0.03%
iShares Biotechnology ETF
Proporción0.02%
SPDR S&P International Small Cap ETF
Proporción0.01%
Tema Oncology ETF
Proporción0%
Fidelity Fundamental Small-Mid Cap ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
